Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The serotonin transporter gene promoter polymorphism (5-HTTLPR) has been repeatedly associated with antidepressant response in mood disorder patients, but findings are not consistent across studies. A meta-analysis was performed on 15 studies including data of 1435 subjects. We tested three phenotypes: remission rate, response rate and response rate within 4 weeks using the cochrane review manager. We observed a significant association of the s/s variant of 5-HTTLPR with remission rate (P<0.0001) and both s/s and s/l variants with response rate (P=0.0002). Response rate within 4 weeks was associated in both models (P=0.003-P<0.00001). This effect is quite robust to ethnic differences although a significant heterogeneity is present in Asian samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“L-alleles result in greater mRNA transcription and more active 5-HTT function (Parsey et al., 2006) and have been associated with a better treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants although discrepant findings exist (Serretti et al., 2007).”
From Affective Cognition and its Disruption in Mood Disorders (2011) · cites this paper as Serretti et al., 2007
Citations
Cites
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Hu, X.-Z., Lipsky, R. H., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B. D., Xu, K., Arnold, P. D., Richter, M. A., Kennedy, J. L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,123
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Meta-analysis of genetic association studies
Munafò, M. R., & Flint, J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.06.014 · Cited by 642
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 633
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
“Results, however, have been inconclusive so far [610, 1071, 1181].”
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Serotonin Transporter (5-HTTLPR) Genotype and Amygdala Activation: A Meta-Analysis
Munafò, M. R., Brown, S. M., & Hariri, A. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.016 · Cited by 789
“Interestingly, the opposite direction of this association from that observed in samples of European ancestry has been mirrored in some pharmacogenetic studies in which greater efficacy of selective serotonin reuptake inhibitors has been linked with the S allele in Asians (44,45), although the evidence for this is mixe…”
ResultCognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
“This marker is a predictor of treatment outcome not only in patients treated with conventional monoaminergicacting antidepressants such as SSRIs, but also in patients treated with intravenous ketamine (Salvadore et al., 2011) or by nonpharmacological modalities such as ECT (McCormick et al., 2007), transcranial magnet…”
BackgroundInfluentialOverview of the Genetics of Major Depressive Disorder
Lohoff, F. W. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0150-6 · Cited by 498
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Self-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
“…hand, in Asians an association between s allele and better response was initially reported, though several following studies reported no associations while only few studies found an association with l allele or l/l genotype (see Table 1 and our previous meta-analysis (Serretti et al., 2007b)).”
BackgroundResultInfluentialSelf-citationAffective Cognition and its Disruption in Mood Disorders
Elliott, R., Zahn, R., Deakin, J. F. W., & Anderson, I. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.77 · Cited by 330
The solute carrier 6 family of transporters
Bröer, S., & Gether, U. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01975.x · Cited by 269
“Nonetheless, several studies have linked the short ‘s’ allele to anxiety-related personality traits, increased risk for neuropsychiatric disorders, impulsive behaviour and impaired response to antidepressant treatment (Hahn and Blakely, 2007; Serretti et al., 2007; Homberg and Lesch, 2011).”
BackgroundDepression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
Ma, Y. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.24 · Cited by 270
New perspectives on the neurodevelopmental effects of SSRIs
Homberg, J. R., Schubert, D., & Gaspar, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.003 · Cited by 266
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
“…has been exhaustively covered elsewhere (for reviews and meta-analyses (see Anguelova et al., 2003b; Lotrich and Pollock, 2004; Rees et al., 1997; Serretti et al., 2007b), individuals carrying the s allele have been found to be at moderately increased risk for anxiety disorders and depression,…”
BackgroundLonsdorf, T. B., Weike, A. I., Nikamo, P., Schalling, M., Hamm, A. O., & Öhman, A. (2009) · Psychological Science · doi:10.1111/j.1467-9280.2009.02280.x · Cited by 241
Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen, M., Weale, M. E., & Lewis, C. M. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.21 · Cited by 240
World Journal of Pharmaceutical Sciences
(2021) · World Journal of Pharmaceutical Sciences · doi:10.54037/wjps · Cited by 245
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Daws, L. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.004 · Cited by 223
“It is known however, that there is a strong association between treatment resistance to SSRIs and humans carrying the low expressing variant of the SERT (Rausch et al., 2002; Rausch, 2005; Serretti et al., 2007 for reviews).”
InfluentialGenetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226
D2Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis
Zhang, J.-P., Lencz, T., & Malhotra, A. K. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040598 · Cited by 206
“analyses(30), a similar approach used in other pharmacogenetic meta-analyses(30,31).”
Childhood stress, serotonin transporter gene and brain structures in major depression
Frodl, T., Reinhold, E., Koutsouleris, N., Donohoe, G., Bondy, B., Reiser, M., Möller, H.-J., & Meisenzahl, E. M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.8 · Cited by 200
“In turn, this might correspond to the better response of those patients, who carry the L-allele, to antidepressant treatment (Serretti et al, 2007).”
BackgroundMachado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195
Transcriptional regulation at a HTR1A polymorphism associated with mental illness
Le François, B., Czesak, M., Steubl, D., & Albert, P. R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.046 · Cited by 184
Gender differences in antidepressant drug response
Keers, R., & Aitchison, K. J. (2010) · International Review of Psychiatry · doi:10.3109/09540261.2010.496448 · Cited by 185
Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response
Domschke, K., Tidow, N., Schwarte, K., Deckert, J., Lesch, K.-P., Arolt, V., Zwanzger, P., & Baune, B. T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571400039x · Cited by 178
Horstmann, S., Lucae, S., Menke, A., Hennings, J. M., Ising, M., Roeske, D., Müller-Myhsok, B., Holsboer, F., & Binder, E. B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.180 · Cited by 183
Pharmacogenetics of antidepressant response
Porcelli, S., Drago, A., Fabbri, C., Gibiino, S., Calati, R., & Serretti, A. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100059 · Cited by 177
Self-citationKato, M., Fukuda, T., Serretti, A., Wakeno, M., Okugawa, G., Ikenaga, Y., Hosoi, Y., Takekita, Y., Mandelli, L., Azuma, J., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.003 · Cited by 174
Self-citationHow can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177
Ignácio, Z. M., Réus, G. Z., Arent, C. O., Abelaira, H. M., Pitcher, M. R., & Quevedo, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12845 · Cited by 172
Baganz, N. L., Horton, R. E., Calderon, A. S., Owens, W. A., Munn, J. L., Watts, L. T., Koldzic-Zivanovic, N., Jeske, N. A., Koek, W., Toney, G. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800466105 · Cited by 172
“There is evidence that humans carrying the s allele of the 5-HTTLPR, who presumably have lower 5-HTT expression, are more prone to psychiatric disorders and are often resistant to treatment with SSRIs compared with individuals homozygous for the l allele (6, 46).”
BackgroundKenna, G. (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s23462 · Cited by 163
“33 By contrast, the 5-HTT genotype was shown to have no effect on treatment outcome in patients treated with the tricyclic antidepressant nortriptyline (plasma doses 50–150 ng/mL), but L/L patients treated with paroxetine 30 mg/day had significant reductions in HAM-D scores from baseline, suggesting that the genotype…”
InfluentialTreatment-resistant depression: are animal models of depression fit for purpose?
Willner, P., & Belzung, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4034-7 · Cited by 163
Pharmacogenomic testing: Relevance in medical practice
Kitzmiller, J. P., Groen, D. K., Phelps, M. A., & Sadée, W. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10145 · Cited by 172
Moderation of antidepressant response by the serotonin transporter gene
Huezo-Diaz, P., Uher, R., Smith, R., Rietschel, M., Henigsberg, N., Marušiˇ, A., Mors, O., Maier, W., Hauser, J., Souery, D., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.062521 · Cited by 149
The implications of gene–environment interactions in depression: will cause inform cure?
Uher, R. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.92 · Cited by 159
Molecular biomarkers of depression
Gururajan, A., Clarke, G. A., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.011 · Cited by 151
SLC6A4 variation and citalopram response
Mrazek, D. A., Rush, A. J., Biernacka, J. M., O'Kane, D. J., Cunningham, J. M., Wieben, E. D., Schaid, D. J., Drews, M. S., Courson, V. L., Snyder, K. A., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30816 · Cited by 136
“Variations in the promoter region of SLC6A4 (serotonin transporter gene) have been reported to be associated with differential remission rates following selective serotonin reuptake inhibitor (SSRI) medication treatment [Serretti and Artioli, 2004; Serretti et al., 2007].”
BackgroundResultInfluentialThe age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review
Olivier, J. D. A., Blom, T., Arentsen, T., & Homberg, J. R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.09.013 · Cited by 131
“Given that the 5-HTTLPR s-allele moderates the efficacy of SSRIs during adulthood (Serretti et al., 2007), it is plausible that early life SSRI exposure is affected accordingly.”
BackgroundMolteni, R., Cattaneo, A., Calabrese, F., Macchi, F., Olivier, J. D. A., Racagni, G., Ellenbroek, B. A., Gennarelli, M., & Riva, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.014 · Cited by 128
Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., Okamoto, Y., Yamawaki, S., Inoue, T., Kusumi, I., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.002 · Cited by 125
“This suggests that 5HTTLPR could be a predictor of the response to SSRIs (Serretti et al., 2007).”
BackgroundThe ceramide system as a novel antidepressant target
Kornhuber, J., Müller, C. P., Becker, K. A., Reichel, M., & Gulbins, E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.003 · Cited by 138
Qiu, A., Shen, M., Buss, C., Chong, Y.-S., Kwek, K., Saw, S.-M., Gluckman, P. D., Wadhwa, P. D., Entringer, S., Styner, M., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx065 · Cited by 114
“Meta-analyses likewise reveal differential effects of 5HTTLPR on selective serotonin reuptake inhibitors efficacy between Caucasians and Asians (Serretti et al. 2007; Porcelli et al. 2012).”
BackgroundResultInfluentialAssociation of Serotonin Transporter Gene Polymorphisms With Poststroke Depression
Kohen, R., Cain, K. C., Mitchell, P. H., Becker, K., Buzaitis, A., Millard, S. P., Navaja, G. P., Teri, L., Tirschwell, D., & Veith, R. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1296 · Cited by 123
Ontogeny and regulation of the serotonin transporter: Providing insights into human disorders
Daws, L. C., & Gould, G. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.013 · Cited by 116
Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region
Taylor, M. J., Sen, S., & Bhagwagar, Z. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.034 · Cited by 118
“A recent meta-analysis of this topic, published in 2007, included data from 15 studies with 1435 participants (12).”
BackgroundPharmacogenomics of antidepressant drugs
Horstmann, S., & Binder, E. B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.007 · Cited by 129
“001) (Serretti et al., 2007b).”
BackgroundBryant, R. A., Felmingham, K. L., Falconer, E. M., Benito, L. P., Dobson‐Stone, C., Pierce, K. D., & Schofield, P. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.016 · Cited by 132
Biology, Genes, and Resilience: Toward a Multidisciplinary Approach
Bowes, L., & Jaffee, S. R. (2013) · Trauma, Violence, & Abuse · doi:10.1177/1524838013487807 · Cited by 97
Gene-Environment Interactions: Biologically Valid Pathway or Artifact?
Rutter, M., Thapar, A., & Pickles, A. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.167 · Cited by 115
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder
Papakostas, G. I., & Fava, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gipapakostas · Cited by 113
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
“Overall data suggested a role for the 5-HT2A gene in the AD response, although a wider knowledge of this gene is needed in order to better disentangle this issue (Serretti et al., 2007a).”
BackgroundSelf-citationBloch, M. H., Landeros‐Weisenberger, A., Sen, S., Dombrowski, P., Kelmendi, B., Coric, V., Pittenger, C., & Leckman, J. F. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30699 · Cited by 108
“E-mail: michael.bloch@yale.edu Received 11 June 2007; Accepted 14 November 2007 DOI 10.1002/ajmg.b.30699 2008 Wiley-Liss, Inc. [Furlong et al., 1998; Caspi et al., 2003; Sen et al., 2004; Feinn et al., 2005; Serretti et al., 2006].”
BackgroundInfluentialBlood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Understanding risk for psychopathology through imaging gene–environment interactions
Hyde, L. W., Bogdan, R., & Hariri, A. R. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.07.001 · Cited by 102
Verma, R., Cronin, C. G., Hudobenko, J., Venna, V. R., McCullough, L. D., & Liang, B. T. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.07.155 · Cited by 107
Pharmacogenomic biomarkers: new tools in current and future drug therapy
Sim, S. C., & Ingelman‐Sundberg, M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.008 · Cited by 121
Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder
Kato, M., Fukuda, T., Wakeno, M., Okugawa, G., Takekita, Y., Watanabe, S., Yamashita, M., Hosoi, Y., Azuma, J., Kinoshita, T., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30783 · Cited by 105
“In Caucasian subjects there is no heterogeneity across studies suggesting that the l allele carrier had more favorable response to antidepressant than the s allele carrier, while there was a significant heterogeneity across studies in Asian subjects [Serretti et al., 2007a].”
BackgroundMethodResultInfluentialSelf-citationKranzler, H. R., Armeli, S., Tennen, H., Covault, J., Feinn, R., Arias, A. J., Pettinati, H., & Oncken, C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820465fa · Cited by 101
“Variation in SLC6A4, which encodes the 5-HTT, could moderate the response to selective serotonin reuptake inhibitors (SSRIs).(16) A 44-bp repeat insertion polymorphism in the 5-HTT linked promoter region (5-HTTLPR) of SLC6A4 results in long (L) and short (S) alleles.”
BackgroundTreatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 109
Developments in the field of antidepressants, where do we go now?
Artigas, F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.04.013 · Cited by 103
5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression
Bocchio‐Chiavetto, L., Miniussi, C., Zanardini, R., Gazzoli, A., Bignotti, S., Specchia, C., & Gennarelli, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.04.005 · Cited by 111
Artigas, F., Bortolozzi, A. A., & Celada, P. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.10.032 · Cited by 102
“Homozygotes for the long variant (l/l) and heterozygotes (l/s) showed a better response to SSRI than homozygotes for the short variant (s/s) (Smeraldi et al., 1998; Zanardi et al., 2000; Serretti et al., 2007).”
BackgroundCarballedo, A., Amico, F., Ugwu, I., Fagan, A. J., Fahey, C., Morris, D., Meaney, J. F., Leemans, A., & Frodl, T. (2012) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32060 · Cited by 95
“For instance, the association between the serotonin transporter-linked polymorphism (5-HTTLPR/rs25531) and MDD [Serretti et al., 2007].”
BackgroundLester, K. J., & Eley, T. C. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-4 · Cited by 91
“For example being able to estimate on the basis of genetic information, the relative likelihood of response to pharmacotherapy versus psychotherapy would be of considerably greater clinical value than identifying that a particular patient is more or less likely to respond positively to SSRIs.”
ResultInfluentialChau, C. M. Y., Ranger, M., Sulistyoningrum, D., Devlin, A. M., Oberlander, T. F., & Grunau, R. E. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00409 · Cited by 91
“Recent work from our group found that procedural pain/stress exposure (controlling for clinical factors related to prematurity, such as gestational age, postnatal infection, cumulative morphine dose, days of mechanical ventilation, illness severity on day 1, and number of surgeries) was associated…”
BackgroundPharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
Arranz, M. J., & Kapur, S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn114 · Cited by 95
Genes, Environment, and Individual Differences in Responding to Treatment for Depression
Uher, R. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586551 · Cited by 92
Adamec, R. E., Holmes, A., & Blundell, J. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.05.005 · Cited by 101
“For further reviews of the extensive literature linking SERT genotype with risk for stress-related disease, see (Anguelova et al., 2003; Lotrich and Pollock, 2004; Rees et al., 1997; Serretti et al., 2007).”
BackgroundGenetic variants in major depressive disorder: From pathophysiology to therapy
Gonda, X., Petschner, P., Eszlári, N., Baksa, D., Édes, A. E., Antal, P., Juhász, G., & Bagdy, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.002 · Cited by 101
Rutter, M. (2010) · Depression and Anxiety · doi:10.1002/da.20641 · Cited by 91
“article also ignored the published meta-analysis of the 5-HTTLPR association with amygdala activation([26]) and the meta-analysis of the association with selective serotonin reuptake inhibitor efficacy in patients with depression.([28]) Finally, the Risch et al.”
BackgroundKronenberg, S., Apter, A., Brent, D., Schirman, S., Melhem, N., Pick, N., Gothelf, D., Carmel, M., Frisch, A., & Weizman, A. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0144 · Cited by 73
“Our findings are consistent with several previous reports in the adult literature (Smeraldi et al. 1998; Pollock et al. 2000; Zanardi et al. 2000; Zanardi et al. 2001; Serretti et al. 2007), although there have been other studies that have not confirmed these findings (Joyce et al.”
Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results
Laje, G., Perlis, R. H., Rush, A. J., & McMahon, F. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1446 · Cited by 89
Murthy, N. V., Selvaraj, S., Cowen, P. J., Bhagwagar, Z., Riedel, W. J., Peers, P. V., Kennedy, J. L., Sahakian, B. J., Laruelle, M. A., Rabiner, E. A., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.032 · Cited by 97
“The neuronal serotonin transporter (5-HTT) plays a critical role in the regulation of serotonin (5-HT) neurotransmission and drugs targeting the 5-HTT such as selective serotonin re-uptake inhibitors (SSRIs) are used extensively in the management of mood and anxiety disorders.”
BackgroundInfluentialAltar, C. A., Hornberger, J. C., Shewade, A., Cruz, V., Garrison, J., & Mrazek, D. A. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.825579 · Cited by 97
Keers, R., Uher, R., Huezo-Diaz, P., Smith, R. G., Jaffee, S. R., Rietschel, M., Henigsberg, N., Kozel, D., Mors, O. N., Maier, W., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.14 · Cited by 90
Palma‐Gudiel, H., & Fañanás, L. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.011 · Cited by 99
Pharmacogenetics in psychiatry: translating research into clinical practice
Ak, M., Zhang, J.-P., & Lencz, T. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.146 · Cited by 88
Personalized medicine can pave the way for the safe use of CB1 receptor antagonists
Lazáry, J., Juhász, G., Hunyady, L., & Bagdy, G. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.013 · Cited by 99
Brunoni, A. R., Kemp, A. H., Shiozawa, P., Cordeiro, Q., Valiengo, L. D. C. L., Goulart, A. C., Coprerski, B., Lotufo, P. A., Brunoni, D., Perez, A. B. A., et al. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.009 · Cited by 87
“Subjects with allele s possibly display a worse clinical response to serotonergic antidepressants, since they act on the SERT, having their efficacy decreased when the transporter is not functioning optimally (Serretti et al., 2007).”
BackgroundHan, C., Wang, S., Bahk, W., Lee, S.-J., Patkar, A. A., Masand, P. S., Mandelli, L., Pae, C., & Serretti, A. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.4.469 · Cited by 85
Self-citationQuantitative evaluation of serotonin release and clearance in Drosophila
Borue, X., Cooper, S. E., Hirsh, J., Condron, B. G., & Venton, B. J. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.02.013 · Cited by 83
“Polymorphisms affecting serotonin degradation and SERT expression have been associated with depression and anxiety (Lasky-Su et al., 2005; Serretti et al., 2006).”
Pharmacogenetic studies in depression: a proposal for methodologic guidelines
Serretti, A., Kato, M., & Kennedy, J. L. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500477 · Cited by 86
Self-citationPharmacogenomics: The Promise of Personalized Medicine for CNS Disorders
de León, J. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.147 · Cited by 87
“…not published data supporting their use and the literature reflects the conflicting results of these gene associations with serotonin receptors (Kirchheiner et al, 2004; Serretti and Artioli, 2004), although the association with the serotonin transporter looks more promising (Serretti et al, 2007).”
ResultCB1 receptor antagonists: new discoveries leading to new perspectives
Kirilly, E., Gonda, X., & Bagdy, G. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02402.x · Cited by 63
Lee, Y., & Lin, P. (2010) · International Journal of Eating Disorders · doi:10.1002/eat.20732 · Cited by 73
“2006 Italy DSM-IV, SCID Patients with BN 0 125 125 44 (35) 51 (41) 30 (24) Healthy controls 0 94 94 22 (23) 39 (41) 33 (35) Rybakowski et al.”
Brain activation predicts treatment improvement in patients with major depressive disorder
Samson, A. C., Meisenzahl, E., Scheuerecker, J., Rose, E., Schoepf, V., Wiesmann, M., & Frodl, T. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.009 · Cited by 78
“This postulation is supported by the observation that the promoter polymorphism of the serotonin transporter, which is functional relevant for serotonin reuptake, is associated with antidepressant efficacy (Serretti et al., 2007).”
BackgroundPharmacokinetic considerations for current state-of-the-art antidepressants
Wyska, E. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1669560 · Cited by 82
“A meta-analysis of 15 studies demonstrated that LL genotype was associated with higher remission rates in patients on SSRI therapy [121].”
BackgroundDrozda, K., Müller, D. J., & Bishop, J. R. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1398 · Cited by 78
The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
H. Kennedy, S., Downar, J., R. Evans, K., Feilotter, H., W. Lam, R., M. MacQueen, G., Milev, R., V. Parikh, S., Rotzinger, S., & Soares, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523635 · Cited by 76
Min, W., Li, T., Ma, X., Li, Z., Yu, T., Gao, D. F., Zhang, B., Yun, Y., & Sun, X. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1550-3 · Cited by 76
“…heterozygous patients showed the lowest clinical response among the three genotype groups, opposite to some previous observations, in which the S/S genotype was favorable for SSRI response, and L/L carriers had the poorest prognosis (Kim et al. 2000; Yoshida et al. 2002, Serretti et al. 2007).”
ResultSerretti, A., Calati, R., Massat, I., Linotte, S., Kasper, S., Lecrubier, Y., Sens-Espel, R., Bollen, J., Zohar, J., Berlo, J., et al. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e5b0d · Cited by 73
“Overall, there is much more support for the view that pharmacodynamic factors influence antidepressant efficacy more than pharmacokinetic ones (Kato and Serretti, in press; Serretti et al., 2007).”
BackgroundSelf-citationAccelerating response to antidepressant treatment in depression: A review and clinical suggestions
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.001 · Cited by 80
Psychiatric pharmacogenomic testing in clinical practice
Mrazek, D. A. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.1/dmrazek · Cited by 74
Metadata
- Authors
- Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T.
- Affiliations
- University of Bologna (IT)
- Kansai Medical University (JP)
- Corresponding author
- Serretti, A
- Venue
- Molecular Psychiatry
- Published
- 2006-12-05
- Volume
- 12
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1982886582
- Cited by
- 529
- References
- 51
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 44 · 2020: 10 · 2019: 18 · 2018: 22 · 2017: 23 · 2016: 28 · 2015: 29 · 2014: 23 · 2013: 38 · 2012: 39
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- 5-HTTLPR, serotonin transporter gene, promoter polymorphism, selective serotonin reuptake inhibitors, antidepressant response, depression, remission rate, genetic association, ethnic differences, Asian populations
- MeSH terms
- Adult, Aged, Depressive Disorder, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Promoter Regions, Genetic, MEDLINE, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.